Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
Jun 25
|
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
Jun 25
|
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
|
Jun 25
|
Takeda Announces New Assignments of Directors
|
Jun 24
|
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
|
May 14
|
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
Feb 14
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
Jan 2
|
Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
|
Oct 9
|
WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
Jun 24
|
Takeda reports positive data from Phase IIb trial of ITP treatment
|
Jun 24
|
EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
|
Jun 24
|
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
|
Jun 23
|
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
|
Jun 21
|
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
|